RxDoctor Payments Data

Zubin Shah, DO

Ophthalmology · Hickory, NCNPI 1467951814

Payments from drug & device makers

$3,096in general payments, 2019–2025

Across 46 payments — averaging $67.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Notal Vision, Inc.$720
  • Alcon$345
  • NEW World Medical,inc.$281
  • Lensar, Inc.$61
  • AbbVie$52
  • plus $148 from 6 others

What the payments were for

  • Travel & lodging$85936%
  • Food & beverage$1,51764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,096 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,207
Medicare patients
269
Services billed
1,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$36,902
Alphagan PBrimonidine Tartrate18$7,676
LumiganBimatoprost15$7,459
RhopressaNetarsudil Mesylate11$3,536
SimbrinzaBrinzolamide/Brimonidine Tart14$3,332
Prednisolone Acetate92$3,259
Latanoprost254$2,578
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,180
Ketorolac Tromethamine59$1,576
Tobramycin-DexamethasoneTobramycin/Dexamethasone24$1,323
Brimonidine Tartrate49$1,218
Ofloxacin75$883
ErythromycinErythromycin Base44$522
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$514
Dorzolamide Hcl19$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan$52$52,03665 claims
AlconSimbrinza$345$3,33214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →